Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sabestomig - Astrazeneca

Next Previous
Drug Profile

Sabestomig - Astrazeneca

Alternative Names: AZD-7789

Latest Information Update: 11 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenocarcinoma
  • Phase I/II Hodgkin's disease
  • Discontinued Solid tumours

Most Recent Events

  • 04 Sep 2025 AstraZeneca completes a phase I/II trial in Hodgkin's disease (In adults, In the elderly, Second-line therapy or greater, In adolescents) in United Kingdom, Spain, Italy, France, Denmark, Canada (IV, Infusion) (NCT05216835) (EudraCT2021-003569-36)
  • 06 Feb 2025 Discontinued - Phase-I/II for Solid tumours (In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in China, Canada, France, Japan, Netherlands, Moldova, Turkey, Georgia, Spain, USA (IV) before February 2025 (AstraZeneca pipeline, February 2025)
  • 13 Jun 2024 Efficacy, pharmacokinetics and adverse events data from a phase-I/II clinical trials in Hodgkin's disease presented at the 29th Congress of the European Haematology Association (EHA-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top